BRIEF-TG Therapeutics Says Phase 3 Enhance Trial Met Its Primary Endpoint

Tg Therapeutics

Tg Therapeutics

TGTX

0.00

May 27 (Reuters) - TG Therapeutics Inc TGTX.O:

  • ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ENHANCE TRIAL

  • SINGLE INFUSION SAFETY CONSISTENT WITH ESTABLISHED BRIUMVI PROFILE

  • PHASE 3 ENHANCE TRIAL SHOWS BIOEQUIVALENCE FOR SINGLE 600 MG DAY 1 BRIUMVI INFUSION

  • SUPPLEMENTAL BLA FILING FOR CONSOLIDATED BRIUMVI DOSING TARGETED FOR 2H-2026

  • SECONDARY ENDPOINTS CONSISTENT WITH PRIOR STUDIES; NO NEW SAFETY SIGNALS OBSERVED

  • PHASE 3 TRIAL MET ITS PRIMARY ENDPOINT

Source text: ID:nGNX5PWVlt

Further company coverage: TGTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.